Lion TCR Receives FDA IND Clearance for Chronic Hepatitis B Therapy Following Fast Track and Orphan Drug Designations

Lion TCR, a biotechnology company specializing in T-cell receptor (TCR)-based therapies, has achieved three significant regulatory milestones from the U.S. Food and Drug Administration (FDA. The company announced that it received Investigational New Drug (IND) clearance for its treatment targeting chronic hepatitis B. This follows earlier recognition from the FDA, which granted the therapy Fast Track designation and Orphan Drug designation.

The IND clearance allows Lion TCR to proceed with clinical trials for its innovative treatment aimed at addressing chronic hepatitis B, a condition affecting millions worldwide. The Fast Track designation is intended to expedite the development and review of drugs that address unmet medical needs, while the Orphan Drug designation provides incentives for therapies targeting rare diseases or conditions. These combined milestones highlight regulatory support for Lion TCR’s approach to tackling chronic hepatitis B through advanced immunotherapy techniques.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 15, 2025

Author

Mark Chiang